What a Government Considers in Providing Vaccination, and Whether Free Provision Is the Best Policy

Answer

Part (a)

In deciding whether to provide vaccination, a government seeks to maximise society’s welfare, weighing the relevant costs and benefits within the cost–benefit framework and against its constraints. This essay sets out the main considerations: constraints and information, the benefits and costs of provision, and the perspectives of different stakeholders.

Constraints and information. The first consideration is the government’s budget constraint — whether tax revenue is sufficient to fund vaccination for the population; if not, the available choices narrow. A second is the quality of information: the government must estimate the potential benefits and costs accurately, including any long-term side-effects. If side-effects could harm groups with underlying conditions, the government may not make vaccination universal.

Benefits. Vaccination generates significant external benefits: a vaccinated, healthier worker takes less sick leave and is more productive, benefiting employers, and a more productive workforce can attract investment and raise growth. The government weighs these third-party benefits, not just the private benefit to the individual.

Costs. Costs are both explicit — the cost of vaccine doses and the manpower to administer them, financed from tax revenue — and implicit. The key implicit cost is opportunity cost: funds used to buy vaccines cannot build, say, a hospital for an ageing population. The government must set the marginal benefit of provision against this marginal cost.

Stakeholders. Finally, the government considers the perspectives of different groups — for instance, the elderly or those medically ineligible, who may be more prone to side-effects — so as to minimise harm, and it gathers information to make the decision well.

Consolidation. The decision reduces to a marginal calculation: the government should provide vaccination up to the point where the marginal social benefit equals the marginal social cost. Where the additional benefit of one more vaccinated person exceeds the additional cost — as is likely given the large external benefits — provision is warranted; the various constraints, costs and stakeholder considerations shape how far and to whom it extends.

Part (b)

A government intervenes at the microeconomic level to pursue efficiency — an allocation that maximises society’s welfare — and equity — a fair distribution of resources. Because vaccination generates positive externalities and is subject to imperfect information, the market under-consumes it. The question is whether free provision (a full subsidy) is the best policy for these objectives. My thesis is that free provision is the best policy where the external benefit is large and access is the binding problem — as in a pandemic — but it is not best in general, because it risks over-subsidy and ignores the information root-cause; the best policy depends on the source and size of the failure.

Free provision may be the best policy. With a large positive externality, the socially optimal quantity Qs lies well above the free-market Qm. A full subsidy equal to the marginal external benefit lowers MPC to MPC(with subsidy); when the optimal quantity coincides with a zero price, vaccination is effectively provided free, achieving Qs and hence efficiency. Free provision also serves equity: in a free market the lower-income would be priced out, but free vaccination makes it accessible to all. In a pandemic, where rapid universal coverage is paramount, this is decisive.

Free provision may not be the best policy. First, a full subsidy strains the budget, with an opportunity cost — funds diverted from, say, education, itself a merit good, worsening efficiency there. Second, where the divergence between MSB and MPB is small, a full subsidy over-corrects: it pushes consumption beyond Qs, creating a new deadweight loss from over-consumption — a worse outcome than the original under-consumption. Third, free provision does not address the root cause where that cause is imperfect information: consumers under-consume because they underestimate the actual benefit, so an information campaign that raises perceived benefit towards actual benefit may achieve Qs more cheaply and durably than a blanket subsidy. Fourth, a uniform subsidy is itself inequitable and costly to tailor, since the external benefit differs across individuals.

Judgement. Whether free provision is best depends on the budget, the type of vaccination and the source of the failure. Where the government can afford it (Singapore could draw on past surpluses) and the externality is large and access is the binding constraint — a pandemic vaccine of urgent, society-wide importance — free provision is the best policy, securing both efficiency and equity quickly. But where the divergence is modest, the budget is tight, or the failure is primarily one of information, free provision is not best: a targeted subsidy combined with provision of information achieves the microeconomic objectives at lower cost and with less risk of over-correction. The best policy is therefore contingent: free provision is optimal for high-externality, access-critical cases, but a calibrated mix is superior in general.